Alpha Cognition (NASDAQ:ACOG) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Alpha Cognition (NASDAQ:ACOG) posted its quarterly earnings data on Thursday. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.04, Zacks reports. The company had revenue of $3.53 million for the quarter, compared to analysts’ expectations of $3.42 million. Alpha Cognition had a negative net margin of 232.23% and a negative return on equity of 62.07%.

Here are the key takeaways from Alpha Cognition’s conference call:

• ZUNVEYL commercialization accelerated in Q1 2026, with net product revenue rising 40% sequentially to $3.5 million and March delivering the strongest demand month since launch, with April said to be even stronger.
• Commercial adoption metrics improved across the board: bottles dispensed rose 23%, active HCP writers increased to 1,060, and nursing homes with prescriptions grew 25%, while repeat prescribing and repeat facility orders remained strong.
• The company reiterated its 2026 operating expense guidance of $54 million to $58 million and said it remains on track to reach operating profitability in 2027, supported by a $54.2 million cash balance and no debt.
• Alpha Cognition said its real-world evidence studies are advancing faster than expected, with BEACON enrollment expected to finish this quarter and top-line data due by early Q3, while CONVERGE and RESOLVE are also set to progress in 2026.
• The company strengthened its intellectual property around ZUNVEYL with two new U.S. patents extending protection through 2045, and it highlighted a large addressable opportunity for its traumatic brain injury program.

Alpha Cognition Stock Up 6.0%

NASDAQ:ACOG opened at $6.02 on Friday. The company’s 50 day moving average price is $6.07 and its 200-day moving average price is $5.92. Alpha Cognition has a 52 week low of $4.50 and a 52 week high of $11.54. The stock has a market cap of $131.06 million, a price-to-earnings ratio of -4.46 and a beta of 2.38.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ACOG. Wall Street Zen downgraded Alpha Cognition from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. Craig Hallum began coverage on Alpha Cognition in a report on Friday, April 17th. They set a “buy” rating and a $14.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Alpha Cognition in a research note on Monday, April 27th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $16.00.

Institutional Trading of Alpha Cognition

A number of large investors have recently made changes to their positions in the stock. Opaleye Management Inc. grew its holdings in shares of Alpha Cognition by 1,698.5% in the fourth quarter. Opaleye Management Inc. now owns 2,070,784 shares of the company’s stock valued at $13,460,000 after purchasing an additional 1,955,642 shares in the last quarter. AWM Investment Company Inc. raised its stake in Alpha Cognition by 52.6% during the fourth quarter. AWM Investment Company Inc. now owns 1,672,168 shares of the company’s stock valued at $10,869,000 after purchasing an additional 576,516 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in Alpha Cognition during the fourth quarter valued at $2,372,000. Cable Car Capital LP lifted its position in Alpha Cognition by 68.8% during the second quarter. Cable Car Capital LP now owns 869,002 shares of the company’s stock valued at $8,108,000 after purchasing an additional 354,278 shares during the last quarter. Finally, Sphera Funds Management LTD. grew its stake in shares of Alpha Cognition by 67.6% in the 4th quarter. Sphera Funds Management LTD. now owns 567,616 shares of the company’s stock worth $3,690,000 after buying an additional 228,864 shares in the last quarter.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.